Daily fluctuations in movement capacity and dyskinesias are well recognized as the two major complications emerging after chronic levodopa treatment. Progressive loss of efficacy leading to severe disability and immobility is a very rare finding, most often reflecting pathological involvement beyond
Pharmacokinetic characteristics of agents applied in the treatment of Parkinson’s disease
✍ Scribed by Masahiro Nomoto; Masahiro Nagai; Akiko Nakatsuka; Noriko Nishikawa; Hayato Yabe; Hiroyoko Moritoyo; Takashi Moritoyo; Takuo Nomura
- Publisher
- Springer
- Year
- 2006
- Tongue
- English
- Weight
- 480 KB
- Volume
- 253
- Category
- Article
- ISSN
- 0340-5354
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The objective of this study was to use the Lille Apathy Rating Scale to assess apathy in a large population of Parkinson's disease (PD) patients and identify several different apathy profiles. One hundred fifty‐nine patients with probable PD and 58 healthy controls participated in the s
## Abstract To assess the patterns of drug use in Parkinson's disease in Spain, information about the clinical characteristics and current treatment of 1,803 parkinsonian patients was obtained from a nationwide survey, involving 241 physicians with practice based on the different assistance levels
## Abstract The sequence effect (SE) in Parkinson's disease (PD) is progressive slowing of sequential movements. It is a feature of bradykinesia, but is separate from a general slowness without deterioration over time. It is commonly seen in PD, but its physiology is unclear. We measured general sl